Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd
Your view on RECEF
Overview
What the company does, where it operates, and who runs it.
About Recce Pharmaceuticals Ltd
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James Hamilton-Bray Graham
- Headquarters
- Aurora Place, Sydney, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James Hamilton-Bray Graham
- Headquarters
- Aurora Place, Sydney, NSW, AU
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S.
aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017.
Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Recce Pharmaceuticals Ltd, and the rating behind it. RECEF last traded at $0.22; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Recce Pharmaceuticals Ltd. Starting points for Recce Pharmaceuticals Ltd: EPS -$0.05, beta 0.21 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Recce Pharmaceuticals Ltd. Recce Pharmaceuticals Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Recce Pharmaceuticals Ltd. Trailing twelve-month EPS for Recce Pharmaceuticals Ltd stands at -$0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Recce Pharmaceuticals Ltd. Recce Pharmaceuticals Ltd has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Recce Pharmaceuticals Ltd valued side by side against its closest peers. Recce Pharmaceuticals Ltd is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Recce Pharmaceuticals Ltd, and how their positions are changing. At a $76.5M market value, institutional positions materially move Recce Pharmaceuticals Ltd's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Recce Pharmaceuticals Ltd executives and directors. Shares of Recce Pharmaceuticals Ltd have traded between $0.22 and $0.60 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Recce Pharmaceuticals Ltd. Recce Pharmaceuticals Ltd is a $76.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Recce Pharmaceuticals Ltd. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Recce Pharmaceuticals Ltd. Coverage tracks Recce Pharmaceuticals Ltd within Biotechnology (Healthcare). Press releases and market coverage, newest first.